ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Back to Protocols
Beginner
8 weeks

Gut Repair Protocol

GI healing, gut lining repair, inflammation reduction, and microbiome support

Peptide Stack

Preparation

Reconstitute all peptides with bacteriostatic water. BPC-157 can be taken orally or injected subcutaneously. KPV and LL-37 are injected subcutaneously. Store at 2-8°C.

Administration

BPC-157 twice daily (oral or subcutaneous). KPV daily (subcutaneous). LL-37 twice weekly (subcutaneous). For oral BPC-157, take on empty stomach. Rotate injection sites if injecting.

Monitoring

Track digestive symptoms, bowel movements, abdominal pain, bloating, and overall gut comfort daily. Most users report improvements within 1-2 weeks. Continue for full 8 weeks for deep healing.

Expected Timeline

Week 1-2: Reduced acute inflammation and pain. Week 3-4: Improved gut lining integrity and reduced symptoms. Week 5-8: Continued mucosal healing and microbiome balance. Maintain results with diet and lifestyle.

Research Basis

BPC-157 is the cornerstone for mucosal healing with extensive GI research. KPV provides anti-inflammatory action via alpha-MSH pathway. LL-37 offers antimicrobial defense. Together, they address multiple aspects of gut health.

Safety Considerations

  • Generally very well tolerated
  • Avoid during pregnancy or breastfeeding
  • Monitor for changes in bowel habits
  • Combine with gut-friendly diet for best results
  • Consult with a healthcare professional before starting
  • This protocol is for research and educational purposes only

Protocol Overview

A GI-focused healing protocol for gut lining repair, inflammation reduction, and microbiome support. BPC-157 is the cornerstone for mucosal healing, supported by KPV's anti-inflammatory action and LL-37's antimicrobial defense.

Duration: 8 weeks Peptides: 3 Experience Level: Beginner

Peptide Stack

BPC-157

  • Dose: 250-500 mcg
  • Frequency: twice daily
  • Timing: morning and evening

View BPC-157 Profile

KPV

  • Dose: 500 mcg
  • Frequency: daily
  • Timing: morning

View KPV Profile

LL-37

  • Dose: 2-5 mg
  • Frequency: twice weekly
  • Timing: any time of day

View LL-37 Profile

Preparation

Reconstitute all peptides with bacteriostatic water. BPC-157 can be taken orally or injected subcutaneously. KPV and LL-37 are injected subcutaneously. Store at 2-8°C.

Administration

BPC-157 twice daily (oral or subcutaneous). KPV daily (subcutaneous). LL-37 twice weekly (subcutaneous). For oral BPC-157, take on empty stomach. Rotate injection sites if injecting.

Monitoring

Track digestive symptoms, bowel movements, abdominal pain, bloating, and overall gut comfort daily. Most users report improvements within 1-2 weeks. Continue for full 8 weeks for deep healing.

Expected Timeline

Week 1-2: Reduced acute inflammation and pain. Week 3-4: Improved gut lining integrity and reduced symptoms. Week 5-8: Continued mucosal healing and microbiome balance. Maintain results with diet and lifestyle.

Research Basis

BPC-157 is the cornerstone for mucosal healing with extensive GI research. KPV provides anti-inflammatory action via alpha-MSH pathway. LL-37 offers antimicrobial defense. Together, they address multiple aspects of gut health.

Safety Considerations

  • Generally very well tolerated
  • Avoid during pregnancy or breastfeeding
  • Monitor for changes in bowel habits
  • Combine with gut-friendly diet for best results
  • Consult with a healthcare professional before starting
  • This protocol is for research and educational purposes only

Disclaimer: This protocol is for educational and research purposes only. It is not medical advice. Consult with a qualified healthcare professional before starting any peptide protocol. These compounds are not approved by the MHRA for human therapeutic use.

Important Disclaimer: This protocol is for educational and research purposes only. It is not medical advice. Consult with a qualified healthcare professional before starting any peptide protocol. These compounds are not approved by the MHRA for human therapeutic use.